Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study
to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and
exploratory efficacy of nebulized CSL787 after administrations of single (SAD) ascending
doses in healthy subjects and multiple (MAD) ascending doses in subjects with NCFB.